2018 American Transplant Congress
12-Months Evolution of Anti-HLA Antibodies Donor Specific Antibodies after Rescue Switch from CNi-Based Immunosuppressive Regimen to Belatacept in Kidney Allograft Recipients
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Effect and Reasons of Rescue Switch to Belatacept among 73 Calcineurin-Inhibitors Treated Kidney Allograft Recipients – A Three Years Retrospective Cohort, Single Center Study
IntroductionAfter kidney transplantation, long-term immunosuppression with calcineurin inhibitors (CNIs) or mTOR inhibitors (mTORi) leads to adverse effects, such as nephrotoxicity and proteinuria. Currently, available data…2018 American Transplant Congress
Incidence of Rejection and Antibody Formation after Immunosuppression Reduction in Patients with Biopsy Proven Polyomavirus Nephropathy
University of North Carolina, Chapel Hill, NC.
The purpose of this study is to determine the incidence of rejection and donor specific antibody (DSA) formation after immunosuppression reduction in patients with biopsy…2018 American Transplant Congress
Development of a Classification of Immunosuppressant Medication Nonadherence Tool to Enable the Objective Measurement of Immunosuppressant Medication Nonadherence in Kidney Transplant Patients
Imperial College Renal and Transplant Centre, London.
IntroductionKDIGO define nonadherence to immunosuppression as a 'deviation from the prescribed medication regimen sufficient to adversely influence the regimen's intended effect'. There is however, no…2018 American Transplant Congress
Delayed Achievement of Therapeutic Tacrolimus Levels after Renal Transplantation is Not Associated with Increased Incidence of Early Acute Rejection: Single-Center Results
Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, WA.
Induction therapy followed by maintenance with a calcineurin inhibitor aims to minimize the incidence of early rejection and optimize the potential for allograft function. However…2018 American Transplant Congress
Immunophenotype of Cells Infiltrating the Graft Explains the Benefits of Belatacept
Previously, we found greater amounts of FoxP3 cells and lower amounts of CD4+/IL-17A+ and senescent cells in belatacept (Bela) patients compared to patients under cyclosporine…2018 American Transplant Congress
Burden of Infectious Complications after Upper Extremity Allotransplantation: A Matched Cohort Study
This study aimed to assess the infectious risk after upper extremity allotransplantation (UEA), a non-vital transplantation procedure requiring lifelong immunosuppression. A matched cohort study was…2018 American Transplant Congress
Efficacy and Safety of Bleselumab in Kidney Transplant Recipients: A Phase 2, Randomized, Open-Label Study
Introduction: Bleselumab (ASKP1240) is an anti-CD40 monoclonal antibody currently in development. This phase 2, randomized, open-label study assessed the efficacy and safety of bleselumab in…2018 American Transplant Congress
Opportunistic Infections after Kidney Transplantation Are Independent Risk Factor of Kidney Allograft Loss: A Retrospective Cohort Study
BackgroundCurrently, kidney allograft survival improved, use of depleting antibodies increased anddonor and recipient became older. In this context, no recent study reported epidemiology of opportunistic…2018 American Transplant Congress
The Effect of Steroid Maintenance in Recipients with Pancreas Transplant Alone: A Single Center Experience
Background: In solid organ transplantation, the use of steroids for maintenance therapy is common. However, the appropriateness of steroid maintenance or withdrawal in pancreas transplantation…
- « Previous Page
- 1
- …
- 66
- 67
- 68
- 69
- 70
- …
- 138
- Next Page »